(Q33834499)

29 July 2017

title

Structure-based repurposing of FDA-approved drugs as TNF-α inhibitors (English)

1 reference

29 July 2017

1

Chung-Hang Leung

1 reference

29 July 2017

Daniel Shiu-Hin Chan

2

1 reference

29 July 2017

Maria Hiu-Tung Kwan

3

1 reference

29 July 2017

Zhen Cheng

4

1 reference

29 July 2017

Chun-Yuen Wong

5

1 reference

29 July 2017

Guo-Yuan Zhu

6

1 reference

29 July 2017

Wang-Fun Fong

7

1 reference

29 July 2017

Dik-Lung Ma

8

1 reference

29 July 2017

publication date

1 March 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

6

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

765-768

1 reference

High-throughput drug discovery: what can we expect from HTS?

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Natural product-likeness score and its application for prioritization of compound libraries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Developing a drug-like natural product library

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Privileged scaffolds for library design and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

The price of innovation: new estimates of drug development costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

21 January 2018

New uses for old drugs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Structure-based strategies for drug design and discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Integration of virtual and high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Tumor necrosis factor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Signalling pathways of the TNF superfamily: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Anti-TNF-alpha antibody therapies in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Small-molecule inhibition of TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Structure-based discovery of natural-product-like TNF-α inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

A natural product-like inhibitor of NEDD8-activating enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Muscarinic receptor antagonists for overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with p

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Anti-TNF-alpha therapies: the next generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

Identification of natural product fonsecin B as a stabilizing ligand of c-myc G-quadruplex DNA by high-throughput virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100016

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CMDC.201100016

1 reference

29 July 2017

1 reference